Biopharmaceuticals

SHERIDAN, WYOMING – May 17, 2025 – Danaher Corporation is reinforcing its position at the forefront of life sciences and diagnostics innovation through its Beacon program—an initiative designed to transform cutting-edge academic research into scalable, market-ready solutions. Spearheaded by Vanessa Almendro, PhD, MBA, Vice President, Head of Science and Technology Innovation at Danaher, the Beacon model exemplifies how strategic academic-industry collaboration can generate high-impact innovations aligned with real-world healthcare and biotechnology challenges.

SHERIDAN, WYOMING – May 17, 2025 – Despite facing one of the most turbulent periods since the biotech industry’s inception in the 1970s, Danaher’s Chief Science Officer, Jose-Carlos Gutierrez-Ramos, believes the sector stands on the cusp of unprecedented progress. In a new commentary, Gutierrez-Ramos outlines why the healthcare and life sciences industries should remain optimistic, citing the explosive growth of GLP-1 receptor agonists, a rapidly evolving pipeline in Alzheimer’s research, and the transformative power of artificial intelligence.

SHERIDAN, WYOMING – May 17, 2025 – Danaher Corporation is spotlighting the rapid progress and growing potential of RNA medicines, reaffirming its strategic commitment to genomic innovation while calling on industry stakeholders to sustain investment in the field. As RNA therapeutics expand across disease areas and delivery methods, Danaher’s leadership is urging the life sciences ecosystem to double down on momentum at what it describes as a defining moment for RNA-based medicine.

Breakthroughs in RNA Delivery and Safety Optimization

SHERIDAN, WYOMING – May 8, 2025 – Roche has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending an update to the European Union (EU) label for Phesgo®, a subcutaneous (SC) fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab), used for treating HER2-positive breast cancer. The label update will allow for Phesgo to be administered outside of clinical settings, such as at patients’ homes, under the supervision of a healthcare professional.